[go: up one dir, main page]

WO2019087239A1 - Agent thérapeutique contre la néphropathie - Google Patents

Agent thérapeutique contre la néphropathie Download PDF

Info

Publication number
WO2019087239A1
WO2019087239A1 PCT/JP2017/039104 JP2017039104W WO2019087239A1 WO 2019087239 A1 WO2019087239 A1 WO 2019087239A1 JP 2017039104 W JP2017039104 W JP 2017039104W WO 2019087239 A1 WO2019087239 A1 WO 2019087239A1
Authority
WO
WIPO (PCT)
Prior art keywords
ipragliflozin
therapeutic agent
nephropathy
administered
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/039104
Other languages
English (en)
Japanese (ja)
Inventor
登與志 井口
真由実 大和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carna Health Support LLC
Original Assignee
Carna Health Support LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carna Health Support LLC filed Critical Carna Health Support LLC
Priority to PCT/JP2017/039104 priority Critical patent/WO2019087239A1/fr
Publication of WO2019087239A1 publication Critical patent/WO2019087239A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Definitions

  • the present invention relates to a therapeutic agent for treating nephropathy.
  • SGLT2 inhibitors are antidiabetic agents that exhibit hypoglycemic action by inhibiting sodium / glucose co-transporter 2 (SGLT2) and promoting urinary glucose excretion
  • SGLT2 inhibitors Clinical applications of six SGLT2 inhibitors have already been conducted (see, for example, Non-Patent Documents 1 and 2).
  • this SGLT2 inhibitor is approved only as a hypoglycemic drug for treating diabetes.
  • this SGLT2 inhibitor has recently been reported to have the possibility of having a nephropathy improving effect at a normal dose, and has been attracting attention, but for use as a therapeutic agent for nephropathy, the mechanism of the hypoglycemic action of this drug
  • side effects based on increased urinary glucose excretion there are problems such as hypoglycemia, polyuria and pollakiuria, dehydration, urinary tract infections and genital infections, and an increase in ketone bodies.
  • the mechanism through the SGLT2 inhibitory effect of the proximal tubule which is the mechanism of the glycemic effect action (promotion of urinary excretion of sodium through SGLT2 inhibition of the proximal tubule) Effects are estimated, and in patients with moderate or higher renal function such as renal failure, the excretion of SGLT2 inhibitors into urine is reduced, so it is thought that no hypoglycemic effect can be obtained, and its use is Not recommended
  • An object of the present invention is to provide a therapeutic agent for treating and / or ameliorating nephropathy.
  • the present inventors are studying the effect of SGLT2 inhibitor as a hypoglycemic drug for diabetes, first of all, the SGLT2 inhibitor acts on the actual dose of the SGLT2 inhibitor. Focusing on the fact that only a small amount has reached the tubule, glucose-induced nephropathy (nephropathy caused by hyperglycemia) at low doses such that existing SGLT2 inhibitors show no hypoglycemic action was found to exert an improvement effect on (PCT / JP2016 / 86657).
  • a low dose of SGLT2 inhibitor has a protective effect even in renal failure model mice not showing hyperglycemia. That is, even in completely different diseases not caused by excessive influx of glucose into renal constituent cells due to hyperglycemia (diseases not caused by hyperglycemia), nephropathy is a mechanism such as suppression of sodium and / or glucose uptake It has been found that the present invention exerts the improvement effect of the present invention.
  • a sodium / glucose cotransporter 2 inhibitor (SGLT2 inhibitor) is used as an active ingredient, and it is used to be administered at a low dose at which no hypoglycemia is observed.
  • Therapeutic agent [2] The therapeutic agent according to the above-mentioned [1], wherein the SGLT2 inhibitor is at least one selected from canagliflozin, ipragliflozin, dapagliflozin, ruseoglyflozin, empagliflozin and tofogliflozin.
  • the therapeutic agent of the above-mentioned [1] or [2], wherein the nephropathy not caused by hyperglycemia is a disease of the kidney based on hyperuricemia.
  • the therapeutic agent according to any one of the above [1] to [3], wherein the nephropathy not caused by hyperglycemia is a disease of the kidney accompanied by an inflammatory reaction of kidney tissue.
  • the therapeutic agent according to any one of the above [1] to [4], wherein the nephropathy not caused by hyperglycemia is a disease of the kidney accompanied by fibrosis of renal tissue stroma.
  • the therapeutic agent of the present invention it is possible to treat nephropathy not caused by hyperglycemia by administration of a low dose having no hypoglycemic action which has not been clinically applied at present. Since the therapeutic agent of the present invention is effective when administered at low doses, hypoglycemia, polyuria, pollakiuria, dehydration, and urinary tract, which are the main side effects due to the urinary glucose excretion promoting action of existing SGLT2 inhibitors. There is no problem such as infection / genital infection, increase of ketone body, and the safety is also extremely high. In addition, since the therapeutic agent of the present invention is not affected by decreased urine output, it is also effective for patients with impaired renal function such as renal failure. At present, considering that there is no chronic renal failure therapeutic agent, the therapeutic agent of the present invention enables a new indication expansion as a nephropathy therapeutic agent.
  • AD represents 0.25% adenine containing diet fed mice.
  • *** represents P ⁇ 0.005 vs ND mice, and “ns” represents no significant difference from ipragliflozin non-administered AD mice. It is a figure which shows the effect of ipragliflozin administration on blood glucose of a renal failure model mouse.
  • FIG. 6 shows the effect of ipragliflozin administration on renal hypertrophy (renal weight corrected for body weight) in renal failure model mice.
  • AD represents 0.25% adenine containing diet fed mice.
  • “***” represents P ⁇ 0.005 vs ND mice
  • # represents P ⁇ 0.05 vs ipragliflozin non-administered AD mice.
  • AD represents 0.25% adenine containing diet fed mice.
  • FIG. 6 shows the effect of ipragliflozin administration on creatinine levels in renal failure model mice.
  • AD represents 0.25% adenine containing diet fed mice.
  • * And "***” represent P ⁇ 0.05 vs ND mice, P ⁇ 0.005 vs ND mice, and "#” and "###” represent P ⁇ 0.05 I plug liflrosin Non-administered AD mice P ⁇ 0.005 ipragliflozin non-administered AD mice.
  • AD-1 is a kidney histology of 0.25% adenine-containing food-fed mice
  • AD-2 is an image of the accumulation site of urate in the kidney tissue of adenine-containing food-fed mice
  • Ipra. (0.1) -1 is a renal histomorphogram of an AD mouse administered with ipragliflozin 0.1 mg / kg / day
  • Ipra. It represents an image of a site where urate accumulates in the kidney tissue of a 1 mg / kg / day-administered AD mouse. The magnification is 200 times. It is a figure which shows the Masson trichrome staining of the kidney tissue of a renal failure model mouse.
  • ND represents the kidney histology of control normal diet consuming mice
  • AD represents the kidney histology of 0.25% adenine containing diet consuming mice
  • Ipra. (0.1) represents a renal histology of AD mice administered ipragliflozin 0.1 mg / kg / day. The magnification is 100 times.
  • the therapeutic agent of the present invention is a therapeutic agent for nephropathy not caused by hyperglycemia, and is characterized in that it comprises an SGLT2 inhibitor as an active ingredient and is administered at a low dose at which hypoglycemia is not observed.
  • Examples of the therapeutic agent of the present invention include a mode in which a low dose of an active ingredient in which hypoglycemia is not observed is contained in a single dose preparation.
  • the SGLT2 inhibitor has a renoprotective effect by a mechanism completely different from tubular SGLT2 suppression at low dose administration which does not recognize the hypoglycemic action currently applied clinically. is there. That is, in the present invention, it has been found that the SGLT2 inhibitor exhibits renal function protective action by suppressing the uptake of sodium and / or glucose into renal constituent cells at low dose administration.
  • the therapeutic agent of the present invention even in nephropathy not exhibiting hyperglycemia, it is considered that the uptake of sodium and / or glucose into renal constituent cells is suppressed to improve the renal function.
  • the SGLT2 inhibitor showed improvement in renal hypertrophy and hematocrit levels of hyperuricemia-based renal failure mice and also showed improvement in creatinine levels. Furthermore, it showed the effect of improving inflammatory cell infiltration and interstitial fibrosis.
  • the nephropathy targeted by the therapeutic agent of the present invention is not particularly limited as long as it is nephropathy not caused by hyperglycemia, and, for example, chronic kidney disease (CKD), acute kidney injury (Acute) (kidney injury; AKI) etc. can be mentioned.
  • CKD chronic kidney disease
  • AKI acute kidney injury
  • diseases of the kidney based on hyperuricemia, nephrosclerosis, nephritis, polycystic kidney, drug-induced nephropathy and the like can be mentioned.
  • the therapeutic agent of the present invention is not affected by decreased urine output, it is also effective for patients with impaired renal function such as renal failure (for example, patients in the fourth stage (renal insufficiency).
  • the SGLT2 inhibitor in the therapeutic agent of the present invention is not particularly limited as long as it binds to SGLT2 and exhibits antagonistic inhibitory action on sodium and / or glucose uptake via SGLT2.
  • SGLT2 inhibitors examples include canagliflozin, ipragliflozin, dapagliflozin, ruseoglyflozin, empagliflozin, tofogliflozin etc.
  • kanagar which is an active ingredient of existing SGLT2 inhibitors, can be exemplified.
  • Glyphrosin hydrate C 24 H 25 FO 5 S 1 ⁇ 2 H 2 O
  • Ipragliflozin L-proline C 21 H 21 FO 5 S • C 5 H 9 NO 2
  • dapagliflozin propylene glycol Hydrate C 21 H 25 ClO 6 ⁇ C 3 H 8 O 2 ⁇ H 2 O
  • Luseoglyph rosin hydrate C 23 H 30 O 6 S x H 2 O
  • empagliflozin C 23 H) 27 ClO 7
  • tofogliflozin hydrate C 22 H 26 O 6 .H 2 O
  • canagliflozin means one having the following canagliflozin structure, and is a pharmaceutically acceptable hydrate, alcohol adduct, amino acid It includes additives and the like.
  • SGLT2 inhibitors such as "ipragliflozin”.
  • the therapeutic agent of the present invention ameliorates nephropathy by a mechanism completely different from the mechanism of promoting urinary glucose excretion by SGLT2 suppression of the proximal tubule, and the dose thereof is as described above, It exerts a nephropathy improving effect at a dose that does not show hypoglycemia. That is, the therapeutic agent of the present invention achieves an effective concentration which inhibits SGLT2 of renal constituent cells such as renal mesangial cells in blood or renal tissue even when low dose administration does not reach the urinary effective concentration of SGLT2 suppression. It acts protectively.
  • a low dose that does not show hypoglycemic action is an amount that does not significantly reduce blood glucose, for example, in the case of the active ingredient of a hypoglycemic drug for which an SGLT2 inhibitor has been approved, the approved minimum dose Means a dose less than the amount.
  • the lower limit may be determined as appropriate as long as the effect is exhibited.
  • canagliflozin hydrate is about 1/100 of the approved minimum dose.
  • Ipragliflozin L-Proline is similar to canagliflozin at the lowest dose with the highest blood concentration (Cmax), and similar IC50 values showing inhibitory activity as well. It is about / 100.
  • the maximum blood concentration (Cmax) at the minimum dose is about 1/10 that of canagliflozin Since the IC50 values are similar, it is about 1/10.
  • canagliflozin hydrate approved as a hypoglycemic agent is less than 100 mg per day (as canagliflozin), may be 90 mg or less, and may be 70 mg or less. 50 mg or less, 30 mg or less, 10 mg or less, or 5 mg or less, and the lower limit thereof is about 1 mg.
  • Ipragliflozin L-Proline is less than 50 mg per day for an adult (as Ipragliflozin), may be 40 mg or less, may be 30 mg or less, may be 20 mg or less, or 10 mg or less It may be 5 mg or less, or 1 mg or less, and the lower limit is about 0.5 mg.
  • Dapagliflozin propylene glycol hydrate is less than 5 mg per day (as dapagliflozin), may be 4 mg or less, may be 3 mg or less, may be 2 mg or less, and 1 mg or less.
  • the lower limit may be about 0.5 mg.
  • ruseogliflozin hydrate it is less than 2.5 mg per day of an adult (as ruseogliflozin), and may be 2 mg or less, 1.5 mg or less, or 1 mg or less. 0.5 mg or less may be sufficient, The minimum is about 0.25 mg.
  • empagliflozin it may be less than 10 mg, may be 9 mg or less, 6 mg or less, 4 mg or less, or 2 mg or less per adult, and the lower limit may be 0 It is about .1 mg.
  • Tofogliflozin Hydrate it is less than 20 mg per day (as Tophogliflozin), may be 18 mg or less, 15 mg or less, 10 mg or less, or 5 mg or less per adult (as Tohogliflozin).
  • the lower limit is about 2 mg.
  • Examples of the administration form of the therapeutic agent of the present invention include for oral use, for injection and the like, but for the same as existing SGLT2 inhibitors (hypoglycemic agents), it is preferable for oral use.
  • forms of the therapeutic agent of the present invention various forms such as tablets, granules, powders, capsules, liquids and the like can be mentioned.
  • the therapeutic agent of the present invention containing the SGLT2 inhibitor as an active ingredient is administered to a patient at a dose at which hypoglycemia is not observed.
  • the method is not particularly limited as long as it is a method, and as described above, oral administration, injection administration and the like can be exemplified as its administration method. Details of the therapeutic agent of the present invention and the dose thereof, and specific examples of the nephropathy to be treated, etc. are as described above.
  • FIGS. 1 and 2 show the results of body weight and blood glucose level in the case of administration of the existing SGLT2 inhibitor ipragliflozin 0.03 mg / kg / day and 0.1 mg / kg / day.
  • ipragliflozin 0.03 mg / kg / day and 0.1 mg / kg / day.
  • FIGS. 1 and 2 show the results of body weight and blood glucose level in the case of administration of the existing SGLT2 inhibitor ipragliflozin 0.03 mg / kg / day and 0.1 mg / kg / day.
  • Example 1 The improvement effect on renal hypertrophy and hematocrit value of AD mice (Adenine-containing diet-ingested mice) at low doses (0.03, 0.1 mg / kg / day) not showing hypoglycemia of ipragliflozin was confirmed.
  • the results are shown in FIG. 3 and FIG. FIG. 3 shows the results of evaluation at a ratio of kidney weight corrected by body weight, and FIG. 4 shows the results of evaluation of hematocrit value.
  • ipragliflozin 0.03, 0.1 mg / kg / day is a dose that does not show hypoglycemia, but as shown in FIG. 3, this ipragliflozin 0.1 mg / kg
  • the hematocrit which is an index of anemia, was also significantly improved by administration of 0.1 mg / kg / day of ipragliflozin.
  • renal anemia is caused by the shortage of erythropoietin. Hematocrit is an indicator of this anemic condition, but its recovery means improvement of nephropathy.
  • Example 2 The improvement effect on creatinine levels of AD mice at low doses (0.03, 0.1 mg / kg / day) in which hypoglycemia of ipragliflozin was not observed was confirmed. The results are shown in FIG. 5 and FIG.
  • ipragliflozin (0.03, 0.1 mg / kg) improved creatinine levels in blood in a concentration-dependent manner .
  • ipragrifin rosin improved the function of the kidney, and creatinine, which is a waste product, was excreted normally. it is conceivable that.
  • Example 3 The improvement effect on pathological change of AD mouse kidney tissue at low dose (0.03, 0.1 mg / kg / day) not showing hypoglycemia of ipragliflozin was confirmed. The results are shown in FIG. 7 and FIG.
  • the therapeutic agent of the present invention has the effect of improving nephropathy not caused by hyperglycemia at low dose administration without hypoglycemia.
  • the therapeutic agent of the present invention enables new indications as a therapeutic agent for renal failure and the like, and is highly useful in industry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le problème que cherche à résoudre l'invention est de fournir un agent thérapeutique qui permet de traiter et/ou d'atténuer une néphropathie non associée à une hyperglycémie. La solution apportée par l'invention concerne un agent thérapeutique contre la néphropathie non associée à une hyperglycémie, qui est caractérisé en ce qu'il contient comme principe actif un inhibiteur du cotransporteur du sodium/glucose de type 2 (SGLT2) et est destiné à être administré à une dose telle qu'elle ne conduit pas à une chute de la glycémie.
PCT/JP2017/039104 2017-10-30 2017-10-30 Agent thérapeutique contre la néphropathie Ceased WO2019087239A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/039104 WO2019087239A1 (fr) 2017-10-30 2017-10-30 Agent thérapeutique contre la néphropathie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/039104 WO2019087239A1 (fr) 2017-10-30 2017-10-30 Agent thérapeutique contre la néphropathie

Publications (1)

Publication Number Publication Date
WO2019087239A1 true WO2019087239A1 (fr) 2019-05-09

Family

ID=66332946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/039104 Ceased WO2019087239A1 (fr) 2017-10-30 2017-10-30 Agent thérapeutique contre la néphropathie

Country Status (1)

Country Link
WO (1) WO2019087239A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) * 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
JP2012517975A (ja) * 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １型糖尿病、２型糖尿病、耐糖能障害又は高血糖の治療用ｓｇｌｔ−２阻害薬
JP2016512817A (ja) * 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) * 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
JP2012517975A (ja) * 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １型糖尿病、２型糖尿病、耐糖能障害又は高血糖の治療用ｓｇｌｔ−２阻害薬
JP2016512817A (ja) * 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Canaglu 100 mg tablets. Package Insert pp. 1-7 , entire document, in particular, ''Composition and Attributes", DOSAGE AND ADMINISTRATION, August 2017 (2017-08-01), pages 1 - 7, Retrieved from the Internet <URL:http://www.info.pmda.go.jp/downfiles/ph/PDF/400315_3969022F1029_1_10.pdf> [retrieved on 20171219] *
"Forxiga 5 mg tablets, Forxiga 10 mg tablets. Package Insert pp. 1-6 , entire document, in particular , ''Composition and Attributes", DOSAGE AND ADMINISTRATION, September 2017 (2017-09-01), pages 1 - 6, Retrieved from the Internet <URL:http://www.info.pmda.go.jp/downfiles/ph/PDF/670227_3969019F1102_2_06.pdf> [retrieved on 20171219] *
"Jardiance 10 mg tablets, Jardiance 25 mg tablets. Package Insert pp. 1-6 , entire document, in particular, ''Composition and Attributes", DOSAGE AND ADMINISTRATION, 17 October 2017 (2017-10-17), pages 1 - 6, Retrieved from the Internet <URL:http://www.info.pmda.go.jp/downfiles/ph/PDF/400315_3969022F1029_1_10.pdf> [retrieved on 20171219] *
FERRANNINI E. ET AL.: "Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial", DIABETES CARE, vol. 33, no. 10, 2010, pages 2217 - 2224, XP055617711, ISSN: 0149-5992 *
TAHARA A. ET AL.: "Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 130, no. 3, 2016, pages 159 - 169, XP055617720, ISSN: 1347-8613 *
TAJIRI, YUJI: "Dapagli flozin Progress in Medicine", EFFECTS OF SGLT2 INHIBITOR DAPAGLI FLOZIN IN NON-DIABETICS, vol. 36, no. 1, 2016, pages 117 - 120, ISSN: 0287-3648 *

Similar Documents

Publication Publication Date Title
Filippatos et al. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms
Goldstein et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
RU2523552C2 (ru) Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета
Davidson et al. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes
WO2008053982A1 (fr) Composition pour le traitement de l&#39;allergie
MX2013010384A (es) Composiciones y sus usos para tratar hiperucemia y transtornos metabolicos asociados con hiperucemia.
WO2012041898A1 (fr) Combinaison de l&#39;inhibiteur de sglt2 et d&#39;un composé de sucre pour le traitement du diabète
JP6563376B2 (ja) 網膜症治療剤
CA2574450A1 (fr) Methode pour traiter l&#39;hyperphosphatemie au moyen d&#39;hydroxycarbonate de lanthane
Brooks et al. Dapagliflozin for the treatment of type 2 diabetes
JP2019112472A (ja) 網膜症治療剤
WO2019087239A1 (fr) Agent thérapeutique contre la néphropathie
JP6563375B2 (ja) 腎症治療剤
KR20120083889A (ko) 당뇨병의 예방을 위한 설폰아마이드
JP6831961B2 (ja) 網膜疾患治療剤
US11382925B2 (en) Agent for treating retinal disease
CN1440287A (zh) 治疗外周血管疾病、外周神经病和自主神经病的方法
MacEwen et al. Drugs for diabetes: part 8 SGLT2 inhibitors
Okonogi et al. Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury
Wu et al. Hepatic phosphoenolpyruvate carboxykinase expression after gastric bypass surgery in rats with type 2 diabetes mellitus
Fahmy et al. Pharmacological Insights into Dipeptidyl Peptidase-4 Inhibitors: Therapeutic Applications and Future Perspectives
Mohammad et al. Effects of metformin and dapagliflozin on glycemic indices and HOMA-IR in type 2 diabetes mellitus patients
WO2020230251A1 (fr) Agent thérapeutique contre des maladies de la rétine
JP2025140338A (ja) 薬剤性腎障害緩和薬
Halalau et al. Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: The CREDENCE Randomized Trial

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17930449

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17930449

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP